Florida International University

FIU Digital Commons
Environmental Health Sciences

Robert Stempel College of Public Health & Social
Work

8-8-2017

Mitochondrial division inhibitor-1 is
neuroprotective in the A53T-α-synuclein rat model
of Parkinson’s disease
Simone Bido
University of Bordeaux; CNRS, Institut des Maladies Neurodégénératives

Federico N. Soria
University of Bordeaux; CNRS, Institut des Maladies Neurodégénératives

Rebecca Z. Fan
Plymouth University; Florida International University

Erwan Bezard
University of Bordeaux; CNRS, Institut des Maladies Neurodégénératives

Kim Tieu
Department of Environmental Health Sciences, Florida International University, ktieu@fiu.edu

Follow this and additional works at: https://digitalcommons.fiu.edu/eoh_fac
Part of the Medicine and Health Sciences Commons
Recommended Citation
Bido, Simone; Soria, Federico N.; Fan, Rebecca Z.; Bezard, Erwan; and Tieu, Kim, "Mitochondrial division inhibitor-1 is
neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease" (2017). Environmental Health Sciences. 14.
https://digitalcommons.fiu.edu/eoh_fac/14

This work is brought to you for free and open access by the Robert Stempel College of Public Health & Social Work at FIU Digital Commons. It has
been accepted for inclusion in Environmental Health Sciences by an authorized administrator of FIU Digital Commons. For more information, please
contact dcc@fiu.edu.

www.nature.com/scientificreports

OPEN

Received: 7 April 2017
Accepted: 23 June 2017
Published online: 8 August 2017

Mitochondrial division inhibitor-1
is neuroprotective in the A53T-αsynuclein rat model of Parkinson’s
disease
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1,2

& Kim Tieu

3,4

Alpha-synuclein (α-syn) is involved in both familial and sporadic Parkinson’s disease (PD). One of the
proposed pathogenic mechanisms of α-syn mutations is mitochondrial dysfunction. However, it is not
entirely clear the impact of impaired mitochondrial dynamics induced by α-syn on neurodegeneration
and whether targeting this pathway has therapeutic potential. In this study we evaluated whether
inhibition of mitochondrial fission is neuroprotective against α-syn overexpression in vivo. To
accomplish this goal, we overexpressed human A53T-α- synuclein (hA53T-α-syn) in the rat nigrostriatal
pathway, with or without treatment using the small molecule Mitochondrial Division Inhibitor-1
(mdivi-1), a putative inhibitor of the mitochondrial fission Dynamin-Related Protein-1 (Drp1). We show
here that mdivi-1 reduced neurodegeneration, α-syn aggregates and normalized motor function.
Mechanistically, mdivi-1 reduced mitochondrial fragmentation, mitochondrial dysfunction and
oxidative stress. These in vivo results support the negative role of mutant α-syn in mitochondrial
function and indicate that mdivi-1 has a high therapeutic potential for PD.
Parkinson’s disease (PD) is the second most common chronic neurodegenerative disorder after Alzheimer’s disease. It has been estimated that up to 10 million people worldwide are affected by PD. This number will drastically increase over time with our aging population. Disease-modifying therapies for this devastating disorder
are urgently needed. We recently demonstrated that blocking Dynamin-Related Protein-1 (Drp1), a mitochondrial fission protein, rescued synaptic dysfunction and prevented cells death in the 1-methyl-4-phenyl-1,2,3,6
-tetrahydropyridine (MPTP)-treated and Pink1-knockout mouse models of nigrostriatal dysfunction1, suggesting
the potential clinical relevance to PD. The broad applicability of this therapeutic strategy and its translational
potential in PD were investigated in the α-synuclein (α-syn) rat model in this study.
Available abundantly in presynaptic terminals, α-syn is a small 14 kDa protein that has received significant
attention since it was discovered twenty years ago as the first genetic mutation in PD2–5. Recent genome-wide
association studies have identified SNCA (that encodes α-syn) as a major gene associated with sporadic PD6–8.
Identifying pathogenic mechanisms and effective therapies for α-syn neurotoxicity is thus relevant to familial,
sporadic PD and other synucleinopathies. Although the exact physiological function of α-syn is still incompletely
understood, missense mutations (A53T, A30P, E46K, H50Q and G51D) or gene multiplication mutations leading
to higher levels of wild type α-syn cause autosomal-dominant PD2–5, 9, 10. α-syn is natively unfolded in solution11,
but it has a propensity to form aggregates under various pathological conditions12. The aggregated and insoluble fibrillar form of α-syn constitutes a major component of the intracellular proteinaceous inclusions called
Lewy bodies. Many interrelated pathogenic mechanisms of α-syn mutations have been proposed13–15, including
mitochondrial dysfunction. Relevant to the present study, α-syn has been reported in recent years to induce
severe mitochondrial fragmentation both in vitro and in vivo, although it is still a topic of debate whether this
defect is a result of increased fission, impaired fusion or both, or reduced connectivity between mitochondria and
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endoplasmic reticulum16–20. However, the clinical relevance of targeting mitochondrial dynamics has not been
determined in α-syn animal models.
Mitochondrial dynamics are controlled by fission and fusion proteins. Fusion requires the coordination of
both the inner (IMM) and the outer (OMM) mitochondrial membranes. The OMM proteins Mitofusin 1 & 2
(Mfn1/2) coordinate with the IMM Optic Atrophy-1 (Opa1) to join the membrane. Mitochondrial Fission Factor
(Mff), Fission-1 (Fis1), as well as Mitochondrial Dynamics Proteins of 49 and 51 kDa (MiD49 and MiD51, respectively) are anchored to the OMM where they recruit cytosolic Dynamin-related protein-1 (Drp1), which then
oligomerizes and forms a ring-like structure around the mitochondria to constrict and split them into smaller
ones21. Because Drp1 can bind to multiple fission proteins to sever mitochondria, directly targeting Drp1 is more
effective to block mitochondrial fission. Furthermore, the translational potential of this target is enhanced by the
availability of the small molecule inhibitor.
Mitochondrial division inhibitor (mdivi-1) was first identified as an inhibitor of mitochondrial division in yeast screens of approximately 23,000 compounds22. Its protective effects through blocking mitochondrial fission have been reported in cultured cells23–28 and mouse models1, 26, 29–33 of a wide range of
diseases. We recently characterized its brain and plasma kinetics and demonstrated that it was protective in the
Pink1-knockout and MPTP-treated mouse models of PD1. We report in this study that mdivi-1 is effective against
hA53T-α-syn-induced neurodegeneration, protein aggregation, mitochondrial abnormalities, oxidative stress
and motor impairment in rats.

Results

Mdivi-1 prevents motor function deficits and neurodegeneration. We previously demonstrated
that blocking mitochondrial fission, using whether rAAV-gene transfer technology or mdivi-1 to block Drp1
function, reduced neurodegeneration and synaptic dysfunction in MPTP-treated and Pink1-null mice1. However,
due to the inherent limitations of these models, it was not feasible to assess motor function in those animals. In
our newly developed and characterized virally induced human A53T-α-synuclein (hA53T-α-syn) rat model,
there is progressive motor impairment and neurodegeneration34. Combined with the significant role of α-syn in
PD, this model is highly suitable for testing the translational potential of mdivi-1. As we previously reported34,
four weeks after receiving stereotaxic injection of hA53T-α-syn into the substantia nigra pars compacta (SNc,
Fig. 1a), rats exhibited progressive and severe motor impairment as compared to the control group that received
rAAV-GFP (Fig. 1b). Twice daily intraperitoneal (i.p.) injection of mdivi-1 [20 mg/kg, a dosage regimen that we
previously characterized1], however, completely normalized this abnormality – even up to the 8 week-end point
of this study (Fig. 1b). At the end of this behavioral study, animals were euthanized and further processed for
biochemical and neuropathological alterations.
To correlate the change in striatal dopamine (DA) to motor function, we used High Performance Liquid
Chromatography (HPLC) to quantify striatal DA content in these animals (Fig. 1c–f). Consistent with the
observed motor function, severe DA depletion was detected after 8 weeks of expressing hA53T-α-syn (Fig. 1c).
Other metabolites of DA were not affected (Fig. 1d,e). hA53T-α-syn also accelerates the turnover rate of DA
(Fig. 1f ). Mdivi-1 prevented the reduction of DA (Fig. 1c) and its high turnover rate (Fig. 1f ) induced by
hA53T-α-syn. Of note, mdivi-1 did not affect the total levels of DA and its metabolites in the GFP control animals, suggesting that blocking Drp1 does not have a detectable detrimental effect on healthy neurons.
Next, we performed stereological cell counting for accurate measure of the population of nigral dopaminergic
neurons in these animals. Density of striatal dopaminergic fibers was also quantified. Consistent with the alterations in motor function and striatal DA content, hA53T-α-syn induced a dramatic loss of nigral dopaminergic
neurons (Fig. 2a,b) and their striatal terminals (Fig. 2c,d). Mdivi-1 treatment conferred a significant protection in
this nigrostriatal pathway. Together, these data strongly support the translational value of using mdivi-1 to reduce
neurodegeneration and associated motor function deficits in PD.
Mdivi-1 reduces proteinase K-resistant and phosphorylated α-synuclein. Aggregated and
phosphorylated α-syn are prominent features in PD. Reducing such aggregation has long been proposed as a
therapeutic strategy for this disease. To evaluate if mdivi-1 would reduce such modified α-syn, we performed
immunohistochemistry on coronal sections containing substantia nigra (Fig. 3). In animals with hA53T-α-syn
transduction, significantly increased levels in phosphorylated serine 129 α-syn and proteinase K-resistant α-syn
were detected. However, mdivi-1 significant reduced the levels of these pathogenic α-syn forms, despite the fact
that it did not change the overall levels of hA53T-α-syn. Taken together, these results indicate that mdivi-1 is
capable of reducing protein aggregation and toxic phosphorylated α-syn.
Mdivi-1 attenuates mitochondrial fragmentation.

α-syn has been demonstrated to induce severe
mitochondrial fragmentation in a number of cell culture studies16–20. In a recent in vivo study, mice with inducible
expression of hA53T-α-syn in dopaminergic neurons exhibited severe mitochondrial fragmentation in a time
dependent manner prior to axonal damage and progressive loss of these neurons19. However, to date, it is not clear
whether mdivi-1 would prevent mitochondrial fragmentation in a hA53T-α-syn rodent model. To this end, we
performed immunohistochemistry using Heat Shock Protein 60 (HSP60) as a mitochondrial marker and quantified mitochondrial morphology. Consistent with this previous animal study19, we also observed significantly
fewer numbers of mitochondria with tubular morphology in rats that received rAAV9- hA53T-α-syn (Fig. 4).
Mdivi-1 treatment provided protection against such morphological alterations in mitochondria. Although there
was a trend of less tubular and more spherical mitochondria in the GFP control group, the difference is not statistically significant. Nevertheless, the absence of elongated mitochondria as we previously observed in mice1 was
unexpected. Based on our previous extensive dose-response study of this molecule and overexpression of proteins that promote mitochondrial fusion (Mfn2), promote fission (Fis1) and blocking fission (Drp1-K38A)23, it is
SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0
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Figure 1. Mdivi-1 preserves motor function, dopamine levels and dopamine turnover rate against hA53Tα-syn-induced neurotoxicity. (a) Schematic illustration of the experimental design. (b) Sprague Dawley rats
(6 weeks old) were assessed for locomotor function using stepping test. Afterwards, these animals were either
injected with mdivi-1 (20 mg/kg, i.p) or vehicle control twice daily for the whole duration of the experiment.
Three days after the initiation of mdivi-1 treatment, animals were stereotaxically injected with either AAVhA53T-α-syn or AAV-GFPdegron control. Motor function was assessed every second week. Mdivi-1 treatment
prevented motor deficits induced by hA53T-α-syn. HPLC was used to quantify total striatal dopamine (DA)
content (c) as well as DA metabolites, (d) 3,4-Dihydroxyphenylacetic acid (DOPAC) and (e) Homovanillic acid
(HVA). hA53T-α-syn induced significant DA depletion and increased DA turnover as evidenced by the ratio
of DOPAC/DA (f). Mdivi-1 reduced this high turnover rate of DA (e) and restored the normal striatal level of
DA (c). Mdivi-1 had no effect when injected in control animals (GFP). (b) Values are means ± SEM for 7–8 rats
and were analyzed by 2-way ANOVA. (time: F4,135 = 224.5 p < 0.001; treatment: F3,135 = 32.81 p < 0.001; time
x treatment: F12,135 = 5.651 p < 0.001) followed by Tukey multiple comparison test (p < 0.001 versus hA53Tα-syn vehicle injected animals). Data from neurochemistry (c–f) were analysed using two-way ANOVA (AAV
injection: F1,26 = 10.57 p = 0.003; treatment: F1,26 = 7.916 p = 0.009; AAV injection x treatment: F1,26 = 1.984
p = 0.1708) followed by Tukey multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001 compared to A53T
vehicle).

possible that the appearance of this spherical morphology was due to enhanced fission inhibition. In our previous
study, using rat dopaminergic neuronal cells, we observed that mdivi-1 lost the ability to promote mitochondrial elongation in some cells at increasing concentrations. High levels of expression of Mfn2 and Drp1-K38A
produced similar effects23. Together, these results suggest that a gene-dose effect of promoting mitochondrial
elongation is an inverted U-shape response. Further supporting this idea, studies from other laboratories also
observed smaller/fragmented mitochondria in cells with overexpression of Opa135 and Mfn236. Of importance in
the present study is that mdivi-1 prevented mitochondrial fragmentation induced by α-syn-A53T.

Mdivi-1 improves mitochondrial function in striatal synaptosomes. α-syn has been demonstrated
in rodent models to reduce striatal presynaptic DA release19, 37–41 and impair mitochondrial respiration in the
striatum42. Together, these observations are consistent with the critical role of mitochondria in synaptic function.
To address whether blocking Drp1 improved mitochondrial function in the present study, we isolated synaptosomes from the striatum of rats with hA53T-α-syn or GFP with or without mdivi-1 treatment and measured
mitochondrial function using XFe96 Extracellular Flux Analyzer as described43. This technology allows measurement of mitochondrial respiration in relatively small quantity and thus facilitates the assessment in specific brain
regions. As seen in Fig. 5, one week after gene delivery (an early time point that induces about 50% cell death)34,
hA53T-α-syn significantly impaired maximal rate of mitochondrial respiration as compared to the control group,
resulting in reduced spare respiratory capacity (Fig. 5b). These results are consistent with a previous observation
SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0
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Figure 2. Mdivi-1 attenuates nigrostriatal degeneration induced by hA53T-α-syn. (a) Representative pictures
of TH immuno-staining in SNc, scale bar 200 μm. (b) Stereological quantification in SNc showing a decrease
in the total number of TH positive neurons in animals expressing hA53T-α-syn. The decrease was prevented
in A53T rats injected with mdivi-1. (c) Representative pictures of TH staining in striatum. Scale bar 1 mm.
(d) Optical density of TH positive fibers was reduced in rat expressing hA53T-α-syn compared to GFP and
preserved in mdivi-1-treated A53T animals. (b,d) Values are means ± SEM of 7–8 rats analysed using twoway ANOVA (b), AAV injection: F1,26 = 43.79 p < 0.001; treatment: F1,26 = 3.919 p = 0.0584; AAV injection x
treatment: F1,26 = 11.12 p = 0.0026; (d) AAV injection: F1,27 = 7.83 p = 0.009; treatment: F1,27 = 7.664 p = 0.0101;
AAV injection x treatment: F1,27 = 1.504 p = 0.23) followed by Tukey multiple comparison test (*p < 0.05;
**p < 0.01; ***p < 0.001 to A53T vehicle, ^p < 0.05 to A53T mdivi-1).
using human induced pluripotent stem cell (hiPSC) with hA53T-α-syn44. Spare respiratory capacity is the ability
of mitochondria to provide substrate supply and electron transport to response to an increase in energy demand.
A reduction in spare respiratory capacity leads to energy crisis when energy demand exceeds the supply ability of
mitochondria. Indeed, spare respiratory capacity has been considered as a major factor that defines the survival of
the neuron43. Mdivi-1 significantly improved spare respiratory capacity in animals with hA53T-α-syn.

Mdivi-1 prevents oxidative stress.

It is well-established that mitochondrial fragmentation and dysfunction generate oxidative stress. We asked whether oxidative stress also occurred in our animal model and if
so, whether mdivi-1 would reduce it. To address this question, we performed immunohistochemistry to detect
4-hydroxy-2-nonenal (4-HNE), a major product generated from lipid peroxidation as a result of free radical
attack. Eight weeks after AAV-hA53T-α-syn injection in rats, a high level of 4-HNE in nigral dopaminergic
neurons was evident as compared to those transduced with AAV-GFP. Consistent with the effect of mdivi-1 on
preserving mitochondrial morphology and function, mdivi-1 blocked the production of 4-HNE in the group of
animals that received hA53T-α-syn (Fig. 6).

Discussion

As we discussed in our recent reviews13, 14, misfolded α-syn (whether as a result of mutations, exposure to environmental toxins or infection) induces cellular dysfunction and neurodegeneration through several distinct
but non-mutually exclusive mechanisms. For example, because of its strong propensity to bind to membranes,
SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0
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Figure 3. Mdivi-1-mediated neuroprotection is accompanied by a decrease in phospho- and PK-resistant
α-syn. (a) Representative pictures of α-syn immuno-staining in SN of AAV-hA53T-α-syn and AAV-GFP
transduced rats. From left to right: total (endogenous rat α-syn+ human A53T-α-syn), human A53T,
phosphorylated and PK-resistant A53T α-syn. Scale bar 50 μm. (b) When quantified, the expression of total
α-syn is higher in rats injected with hA53T-α-syn and increases further after mdivi-1 treatment, suggesting
mdivi-1 preserved more dopaminergic structures. (c) As expected, higher levels of human α-syn were
detectable in animals with hA53T-α-syn transduction. Mdivi-1 did not affect the total levels of this protein.
(d) The level of phosphorylated α-syn was increased in A53T animals and, mdivi-1 treatment attenuated this
upregulation. (e) Following PK treatment, a strong hA53T-α-syn immunoreactivity persisted in A53T animals.
This signal was significantly reduced in A53T rats treated with mdivi-1. The quantification was carried out
using an automated threshold in one slice per animal. Values are means ± SEM for 7–8 animals analysed by
two-way ANOVA (b) AAV injection: F1,27 = 16.68 p < 0.001; treatment: F1,27 = 3.611 p = 0.0681; AAV injection
x treatment: F1,27 = 3.476 p = 0.0732; (d) AAV injection: F1,27 = 22.69 p < 0.001; treatment: F1,27 = 3.176
p = 0.0859; AAV injection x treatment: F1,27 = 4.066 p = 0.0538; e, AAV injection: F1,27 = 31.45 p < 0.001;
treatment: F1,27 = 5.217 p = 0.0305; AAV injection x treatment: F1,27 = 5.635 p = 0.025) followed by Tukey
multiple comparison test (*p < 0.05; ***p < 0.001 to A53T vehicle, ^^p < 0.01 to A53T mdivi-1)
SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0

5

www.nature.com/scientificreports/

Figure 4. Mdivi-1 reduces mitochondrial fragmentation in dopaminergic neurons induced by hA53T-αsyn. Coronal midbrain sections containing SN of rats after 8 weeks of receiving AAV-hA53T-α-syn or AAVGFPdegron with or without mdivi-1 treatment were immunostained with a mitochondrial marker HSP60
(red) and TH (not shown). Scale bar 5 μm. Different mitochondrial morphologies were categorized into three
populations according to their shapes: tubular, intermediate and spheric (representative pictures bottom
panel a, scale bar 1 μm). (b,c,d) Abundance in different mitochondria populations. Panel B shows a decrease
in the relative number of tubular mitochondria in neurons of rats expressing hA53T-α-syn. This phenotype
was reversed following mdivi-1 treatment. Fluorescent images were captured as single layer. Values are
means ± SEM for 50–80 TH+ neurons per group. Statistical analysis was performed using two-way ANOVA
(b) AAV injection: F1,246 = 8.144 p = 0.0047; treatment: F1,246 = 1.069 p = 0.3023; AAV injection x treatment:
F1,246 = 17.47 p < 0.001;(c) AAV injection: F1,246 = 8.008 p = 0.005; treatment: F1,246 = 1.569 p = 0.2115; AAV
injection x treatment: F1,246 = 0.3536 p = 0.5526) followed by Tukey multiple comparison test (*p < 0.05;
**p < 0.01; ***p < 0.01 to A53T vehicle).

Figure 5. Mdivi-1 attenuates mitochondrial dysfunction in isolated synaptosomes. Mitochondrial function
in striatal synaptosomes was assessed by measuring oxygen consumption rate (OCR) using the XFe96
Extracellular Flux Analyzer. (a) Sequential injections of oligomycin (to inhibit oxygen consumption mediated
by ATP synthase), FCCP (an uncoupler to induce maximal OCR), Rotenone/Antimycin (to inhibit complex
I and III, respectively). Values obtained from (a) were then used to calculate Spare Respiratory Capacity as a
% = (Maximal Respiration)/(Basal Respiration) × 100 (b). Data represent means ± SEM of 5 five animals per
group (except for the GFP+ mdivi-1 group, n = 3), Statistical analysis was performed using two-way ANOVA
(AAV injection: F1,14 = 26.12 p < 0.001; treatment: F1,14 = 4.07 p = 0.063; AAV injection x treatment: F1,14 = 1.19
p = 0.294) followed by Tukey multiple comparison test (*p < 0.05 to A53T vehicle).
α-syn localizes to organelles such as lysosomes, endoplasmic reticulum and mitochondria. Indeed, it has been
well-reported that α-syn impairs the function of these organelles. Combined with its ability to inhibit the
ubiquitin-proteosomal and autophagic pathways, protein aggregation is a common observation in α-syn associated toxicity. In addition to these cell-autonomous mechanisms, α-syn also activates microglia and induces
SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0
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Figure 6. Mdivi-1 decreases ROS-mediated lipid oxidation in A53T animals. (a) Representative pictures of
4-HNE staining (red) measured in TH positive neurons (green). Scale bar 30 μm. (b) Dopaminergic cells of
animals expressing hA53T-α-syn display an increase of lipid oxidation that turned back to basal levels in the
presence of mdivi-1 treatment. Quantification was carried out measuring the levels of grey of 4-HNE staining
in 16-bit images. Fluorescent images are captured as single layer. Values are means ± SEM for 7–8 rats (6 cells
are analysed for each rat) and were analysed by two-way ANOVA (AAV injection: F1,27 = 5.196 p = 0.0308;
treatment: F1,27 = 4.014 p = 0.0552; AAV injection x treatment: F1,27 = 16.91 p < 0.001) followed by Tukey
multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001 to A53T vehicle).
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neuroinflammation, resulting in a non-cell autonomous-mediated toxicity. With such multiple pathogenic mechanisms, various therapeutic strategies have been developed over years to combat α-syn associated pathologies13.
In the present study, we addressed the critical question of whether protecting mitochondrial integrity and function would be sufficient to attenuate α-syn-induced neurotoxicity in vivo.
Using our well-characterized virally induced hA53T-α-syn rat model34, we demonstrated that the putative
Drp1 inhibitor mdivi-1 is highly effective in reducing dopaminergic neurodegeneration and motor dysfunction.
At biochemical and cellular levels, mdivi-1 increased striatal DA content, reduced protein aggregation and oxidative stress, as well as reduced mitochondrial fragmentation and improved mitochondrial function. Altogether
these results support the negative impact of α-syn on mitochondria and that blocking mitochondrial fission is
protective against α-syn neurotoxicity. The results of our study are consistent with the role of α-syn in causing
mitochondrial dysfunction in other in vivo studies. For example, Chesselet et al. demonstrated that mice with
global overexpression of human wild type α-syn in the brain using the Thy1 promoter exhibited age dependent
accumulation of α-syn in mitochondria in the nigrostriatal dopaminergic pathway, impaired electron transport
chain function and enhanced oxidative stress42. Recently, Greenamyre’s laboratory reported that specific forms
of post-translationally modified α-syn bind with high affinity to the mitochondrial receptor TOM20, resulting
in mitochondrial dysfunction and production of reactive oxygen species45. From the Zhuang’s group, inducible
hA53T-α-syn mice exhibited severe mitochondrial fragmentation that preceded dopaminergic neurodegeneration and other pathologies19. Using double immunogold-transmission electron microscopy, presence of the transgenic α-syn protein in mitochondria was clearly identified in these mutant mice. We also observed mitochondrial
fragmentation in our present study using rAAV-hA53T-α-syn rat model. More importantly, for the first time,
we demonstrated that blocking in vivo application of mdivi-1 is highly protective against hA53T-α-syn-induced
neurodegeneration and other associated pathologies. The observation of mdivi-1 reducing accumulation of proteinase K-resistant and phosphorylated Ser129-α-syn is potentially significant. Additional studies are required
to elucidate the mechanism of these effects. However, we hypothesize that the mechanism is mediated, at least
in part, by improving mitochondrial function and reducing oxidative stress, because the autophagic and ubiquitin proteasomal pathways are energy dependent and sensitive to oxidative stress. A recent study has similarly
reported that mdivi-1 reduced the accumulation of amyloid-beta plaque in double transgenic mice APP/PS1
model of Alzheimer’s disease33.
Manipulating mitochondrial fission/fusion has been considered as a potential novel mitochondrial therapy
in recent years46–48. Within this context, blocking Drp1 is the most highly pursued strategy, partly because of the
availability of a putative inhibitor (mdivi-1). Other investigators have demonstrated that blocking Drp1 function
is protective in PD cell culture models of PINK123, LRRK249, 50 or VPS3526 mutations, and of rotenone51, MPP+ 52, 53
or 6-hydroxydopamine54 neurotoxins, as well as in Pink1−/− and MPTP-treated mice1. The protective role of
blocking Drp1 in α-syn cell culture models is not quite definitive. Although some studies demonstrated that
blocking Drp1 protected mitochondria from α-syn, others show that mitochondrial fragmentation induced by
α-syn is Drp1 independent16–18, 20, 55. As often, conflicting data in cell culture models could be difficult to interpret
due to different cell systems and experimental conditions. We believe that evaluations of the translational values
of blocking Drp1 should extend beyond in vitro mitochondrial morphology and function, and that it should be
conducted in mammalian animal models with brain pathologies and motor impairment as seen in PD. In this
regard, the present study has provided some insights.
One potential concern of blocking mitochondrial fission as a therapeutic strategy is the possibility of developing side effects, because a balance of fission and fusion is necessary for the maintenance of neuronal function. This
is an issue that will need to be considered if and when this treatment is to be conducted in clinical trials. Based on
current literature, however, naive wild type mice are viable and no abnormal phenotypes are detectable up to ten
weeks after the treatments of Drp1 inhibition, whether this is achieved by systemic injection of mdivi-11, 28–31, 33, 56–58
or a peptide (P110-TAT)59 or by localized gene therapy1. Cytotoxicity of this molecule was not detectable at
cellular, biochemical and functional levels, as shown in these publications and in the present study. Peripheral
injections of mdivi-1 do not affect blood pressure, oxygen saturation, pH and blood cell counts56. Germline deletion of Drp1, however, induces embryonic lethality and degeneration of Purkinje neurons in mice60–62. Mice with
conditional knockout of Drp163 or Mfn264 also indicate that nigrostriatal dopaminergic neurons are vulnerable
to complete deletion of fission and fusion proteins. Interesting mice with heterozygous deletion of Drp1 have
normal lifespan, phenotype, mitochondrial and synaptic structures65. Crossing these Drp1+/− mice with either the
transgenic AβPP mice (Tg2576) or with Tau P301L transgenic mice reduced toxic soluble proteins and improved
mitochondrial function in these animal models of Alzheimer’s disease66, 67. Together these studies indicate that
there is a gene-dose effect of loss of Drp1 function on its associated negative impact on neuronal function and
viability. Furthermore, partial Drp1 loss of function appears to be safe and sufficient to confer neuroprotection.
Mdivi-1 has been demonstrated independently by many laboratories to have striking protective effects in a
wide-range of disease models both in vitro and in vivo. The interest in the translational potential of this molecule
is therefore understandably high. However, recent studies have raised the question of the specific mechanism of
action of mdivi-1. Initially discovered by Nunnari and colleagues, mdivi-1 was shown to be specific and potent
inhibitor of GTPase activity of yeast Dnm1, a homolog of mammalian Drp122. Subsequently, this small molecule was also demonstrated to block Drp1 GTPase activity in human recombinant Drp168 and in mammalian
neuronal cells28. GTPase activity of Drp1 is required for Drp1 oligomerization. Largely based on evidence from
studies such as these ones, mdivi-1 has been considered in general as a Drp1 inhibitor. However, studies from the
laboratory of Reddy showed that mdvi-1 also increased the levels of mitochondrial fusion proteins (Mfn1/2 and
Opa1) and reduced the levels of Drp1 in neuronal cells27, 28. It has also been demonstrated in vivo to reduce the
levels of phosphorylated Drp1-S616 induced by kainic acid in the mouse hippocampus58. Taken together, these
studies indicate that mdivi-1 is capable of blocking mitochondrial fission and promoting mitochondrial fusion
at both enzymatic and protein expression levels. It is worth noting that also using human recombinant Drp1, a
SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0
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recent study reported that mdivi-1 is a weak and non-specific inhibitor of Drp1 GTPase69. Instead, this molecule
was reported to be a reversible inhibitor of complex I and ROS production generated via reverse electron transfer
mechanism. More studies are clearly required to reconcile this discrepancy and explain why blocking complex I
would confer protection observed in other studies. Rather than using recombinant Drp1, perhaps an intact mammalian cell system should be used to determine whether mdivi-1 would block Drp1 function either directly or
indirectly. Taken together, it is clear so far that mdivi-1 confers striking protective effects across multiple disease
models, but most likely not exclusively through Drp-1 inhibition.
In summary, the present study reports that mdivi-1 is highly effective in reducing neurodegeneration, motor
dysfunction and accumulation of toxic α-syn, mitochondrial damage and oxidative stress in a rat α-syn model
of PD. This study further highlights the translational potential of mdivi-1. In addition to the present study, this
small molecule has been demonstrated to be beneficial in other rodent models of PD1, Huntington’s disease28,
Alzheimer’s disease33, epilepsy58, renal30, cardiac29, brain ischemic damage31, 70, neuropathic pain57 and diabetes32.
With such a striking neuroprotective property in a wide range of diseases, mdivi-1 and perhaps strategies of
blocking Drp1 function hold great promise to novel therapies.

Methods

Antibodies. Primary. Mouse anti-TH (1:10000, 1:2000 for SNc and striatum respectively, clone LNC1,
Millipore); mouse anti-α-synuclein (1:1000, BD Transduction Laboratories); mouse anti-human-α-synuclein
(1:1000, clone LB509, Invitrogen); rabbit anti-α-synuclein-P-S129 (1:1000, Abcam ab59264); goat anti-HSP60
(1:20, Santa Cruz Biotechnology); Rabbit anti-4-HNE (1:200, Alpha Diagnostic).
Secondary. All the secondary antibodies used for the immunofluorescience staining are anti-IgG conjugated
with Alexa FluorTM 488 or 568. For HRP immunohistochemistry labeling, the HRP Dako Envision PolymerTM
conjugated with the appropriate secondary antibody was used.

Animals and experimental design.

All experiments were performed in accordance with the European
Union directive of September 22, 2010 (2010/63/EU) after approval by Institutional Animal Care and Use
Committee of Bordeaux (CE50) under the license number 5012066-A, and in accordance with the provisions
laid down by the UK Home Office under the Project Licence No. PPL 30/3088. Animals had free access to water
and food. Veterinary care includes a full program for prevention of disease, daily observation and surveillance
for animal health, appropriate methods of disease control, diagnosis, and treatment, appropriate methods of handling, restraint, anesthesia, analgesia and euthanasia as well as monitoring of surgical programs and post-surgical
care. One week before surgery, Sprague Dawley rats (32 animals, 6 weeks old), purchased from Charles River,
were tested for stepping test and sorted in order to generate 4 groups with no differences in the mean motor
performance (p > 0.95). The 4 groups were then submitted to different treatments: 1) AAV-GFPdegron plus
vehicle (GFP + veh), 2) AAV-GFPdegron plus mdivi-1 (GFP + mdivi-1), 3) AAV- hA53T-α-syn plus vehicle
(A53T + veh) and 4) AAV- hA53T-α-syn plus mdivi-1 (A53T + mdivi-1).

Mdivi-1 treatment.

As previously described 1 , 3-(2,4-Dichloro-5-methoxyphenyl)-2-sulfanyl4(3H)-quinazolinone (mdivi-1, Sequoia Research Products, UK) was dissolved in DMSO as a stock solution,
which was then diluted with sterile 0.9% saline solution (1% DMSO final concentration), sonicated for 30 seconds
and then promptly injected. Three days before stereotaxic injection of AAV- hA53T-α-syn or AAV-GFPdegron,
animals were pre-treated with either mdivi-1 (20 mg/kg) or vehicle. This dosage was selected based on our previous study1, in which we characterized the in vivo pharmacokinetics and dose-response of mdivi-1. We found that
with this dosage regimen, mdivi-1 conferred the most neuroprotective effects without detectable side-effects. The
intraperitoneal (i.p) injections were performed twice a day (9 a.m.–18 p.m.) for eight weeks. During this period,
every two weeks, motor performance was monitored with the stepping test. At the end of the treatment period
animals were euthanized and brain collected for histological and neurochemical analysis. Brains were collected
fresh and divided in three parts: bilateral mesencephalon and unilateral striatum was post fixed for 5 days in PFA
4% and then sectioned for histological studies, while another striatum was collected fresh, flash frozen and store
at −80 °C for neurochemical analysis.

Viral vector production. AAV9-GFPdegron and AAV9-hA53T-α-syn were produced by triple transfection

into HEK-293T/17 cell line (ATCC, Teddington, UK) in polyethylenimine solution. After seventy-two hours cell
were re-suspended with Tris lysis buffer (NaCl 150 mM, Tris-HCl 50 mM pH 8.5) and lysed using the freeze-thaw
cycle procedure (−80 to +37 °C). The supernatant underwent to iodixanol gradient step purification (by centrifugation), and the fraction enriched in viral vector stocked at −80 °C. These procedure were well established and
well described in our previous publications34, 71.

Surgery procedure. Rats were bilaterally injected with AAV-GFPdegron or AAV- hA53T-α-syn (titer nor-

malized to 6.9 × 1013 gcp/ml) as previously described34. Briefly, under isoflurane anesthesia, animals were sterotaxically injected with 2 μL of virus into the substantia nigra pars compacta (SNc) according to the following
coordinates: AP = −4.9/−5.4, L = −2.2/−2, DV = −7.8 from bregma.

Motor performance assessment. The stepping test was used to assess the forelimb akinesia as we recently

described34. Rats were held and dragged sideways on a smooth surface at a constant speed for 0.9 m of distance
and the number of adjusting steps counted. The performance was evaluated once every two weeks, three sessions

SCIeNtIfIC RePortS | 7: 7495 | DOI:10.1038/s41598-017-07181-0

9

www.nature.com/scientificreports/
over two consecutive days. The scores over the three sessions were averaged and the left and right backhand steps
were pooled together.

HPLC analysis.

Fresh striatum collected after euthanasia was sonicated in HClO4 0.1 M and the homogenate centrifuged at 4 °C for 30 min at 13000 rpm. 20 uL of supernatant was used for the HPLC analysis as previously described72. Monoamines were measured by coulometric detector (Coulochem II, ESA) coupled to a
dual-electrode analytic cell (model 50110) with the potential of electrodes set at +350 and −270 mV. The samples
were injected with a mobile phase containing NaH2PO4 70 mM, methanol 7%, sodium octyl sulfate 100 mg/L, triethylamine 100 μL/L, EDTA 0.1 mM, into an HPLC Equisil column (C18, 150 × 4.5 mm, 5 μm)72. Retention times
for noradrenaline, DOPAC, DA, HVA and serotonin were ~250, 420, 660, 1100, 1970 sec, respectively.

Immunostaining.

Tyrosine Hydroxylase. Free floating 50 μm-thick slices were rinsed in PBS and treated
for one hour with a blocking solution containing BSA 2% and Triton × 100 0.3% in PBS. After being blocked,
the tissue was incubated with the TH primary antibody diluted with a solution containing BSA 1%, Triton × 100
0.3% over night at room temperature. The slices were then incubated with the secondary antibody and finally
revealed with peroxidase EnVisionTM system (DAKO). For the SNc slices the counter coloration with cresyl violet
was performed. The slices were mounted in gelatin-coated slides and the coverslip sealed with EukittTM mounting
medium.

Stereological counting.

The unbiased stereological sampling method was used to quantify dopaminergic
neurons in SNc as described in many occasions34 The cell counting was performed using Leica DM600 motorized
microscope equipped with Mercator Pro Software (Explora Nova, La Rochelle, France). After SNc boundaries
delimitation, TH positive (TH+) cells in SNc are on-line counted at 40X magnification over five 50 μm-thick
sections for each brain, collected every 300 μm, encompassing the whole SNc. The optical fractionator stereological probe was then used to estimate the total number of TH+ neurons for the entire SNc volume. Considering
the bilateral nature of our model, the data presented in this paper are the sum of neurons counted for both SNc.

Striatal TH quantification. Images were taken with Nanozoomer 2.0 HT (Hamamatsu, Japan) at 20X magnification and analyzed with Image J (NIH, USA). The striatum boundaries were traced and optical density measured in terms of grey levels for 8-bit images as previously described34.
α-synuclein immunostaining and quantification. For α-syn immunolabeling we applied the same
protocol as described above for the TH staining as previously73. The slices treated with proteinase K (PK) were
incubated for 10 minutes in a solution with 1 μg/mL of PK prior to any step and the tissue processed for the
immunostaining. SNc pictures were captured with NanoZoomer using 20X objective and analyzed with Image J
software. The quantification was carried out by measuring the percentage of the SNc area occupied by the stained
surface using an automated threshold for all the images.
Mitochondrial network staining in vivo. HSP60 immunostaining was used to characterize the mitochondrial phenotype in dopaminergic neurons of SNc. Free-floating coronal SNc sections of 50 µm thickness
were rinsed in PBS, incubated for 10 min with H2O2 3% and 10% methanol, then for 20 min with Triton × 100 2%.
BSA 3% for 1 hour was used to saturate the unspecific binding site before the overnight incubation with primary
antibody (diluted in a solution containing BSA 1% and Triton × 100 at room temperature. Following incubation,
sections were rinsed three times for 10 min in PBS and incubated for 1 hour with the secondary antibody. The
same protocol was used to co-stain the TH and phosphorylated α-syn. The triple staining was needed to limit
the quantification to dopaminergic neurons (TH positive) expressing hα-syn (indicated by the accumulation of
phospho-syn). Single layer pictures of rat SNc were taken with confocal microscope DM6000 TCS SP5 (Leica,
Germany) using 63 X (1.4 NA) magnification.
Mitochondrial network quantification in vivo.

Every single neuron picture was analyzed through an
Image J macro purposely designed for the quantification of the relative area, shape descriptors and number of
mitochondrial particles occupying the cytoplasmic surface of the neuron. Moreover, the circularity index provided by the macro, allowed us to sort the entire mitochondria population fragments into three different groups
based on their shape: 0.8 to 1 spheric; 0.5 to 0.79 intermediate; 0 to 0.49 tubular.

4-hydroxynonenal staining and quantification.

TH and 4-HNE were co-stained following the same
protocol used for the mitochondrial labeling in vivo. Single layer pictures were captured using confocal imaging
at 40X magnification. We used a fixed laser power and AOTF levels for all the images. 16-bit pictures were then
analyzed with Image J software measuring the level of grays of 4-HNE staining only in TH positive neurons.

Synaptosomes isolation. Synaptosomes were isolated from Sprague Dawley adult rats based on a previous

publication43 but with some modifications. Briefly, striata were quickly removed, rinsed with ice-cold sucrose
buffer (320 mM sucrose, 1 mM EDTA, 0.25 mM dithiothreitol, pH 7.4) and then homogenized (10–12 strokes) in
dounce glass homogenizer containing 1–1.5 mL sucrose buffer. The homogenates were then gently layered onto
a discontinuous Percoll gradient (2.5 ml of 3%, 10% and 23% in sucrose buffer) in 10 mL centrifuge tubes, and
centrifuged at 32,500 g for 10 min at 4 °C in a JA-25.50 fixed angle rotor in a Beckman Avanti J-26 X centrifuge.
The band between 10% and 23% from striatum were collected for synaptosomes, pelleted and resuspended into
ionic buffer (20 mM HEPES, 10 mM D-glucose, 1.2 mM Na2HPO4, 1 mM MgCl2, 5 mM), protein concentrations
were measured using nano drop 2000.
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Mitochondrial function in striatal synaptosomes. Primary based on the method developed by
David Nicoll’s laboratory43, striatal synaptosomes (2ug/well) were plated into an XF96 cell culture microplate
(Seahorse Bioscience Inc.) which was previously sequentially pre-coated with 0.0033% (v/v) polyethyleneimine
(Sigma-Aldrich) and Geltrex (Invitrogen). The plate was centrifuged at 3,400 g for 1 h at 4 °C in a Henttich Rotanta
460 R centrifuge to facilitate attachment. The ionic buffer was then replaced with 175 µL assay buffer (3.5 mM KCl,
120 mM NaCl, 1.3 mM CaCl2, 0.4 mM KH2PO4,1.2 mM Na2SO4, 15 mM D-glucose, 10 mM pyruvate, 0.4% (w/v)
fatty acid-free bovine serum albumin, and 10 mM TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic
acid), pH 7.4). The plate was incubated in a non-CO2 incubator at 37 °C for 10–15 min, then loaded into the
XFe96 Extracellular Flux Analyzer (Seahorse Biosciences Inc.). Mitochondrial function in these synaptosomes,
as indicated by oxygen consumption rate (OCR), was monitored in real-time throughout the assay. Different
parameters of mitochondrial respiration were obtained with sequential injections of 2.5 μg/ml oligomycin, 4 μM
FCCP and 2 μM Rotenone/Antimycin. Oxygen consumption rate data points represent the mean rates of each
measurement cycle, which consisted of 30 s mixing time, 30 s waiting time, followed by 3 min of data acquisition.
Basal respiration was measured before first injection (3 cycles), and 3 data points were obtained following each
injection (12 data points in total).
Statistics. All values are expressed as mean ± SEM. Differences between means were analysed using a
two-way analysis of variance (ANOVA) followed by Tukey multiple comparison post-hoc test using GraphPad
Prism v5.01. The null hypothesis was rejected when P-value was <0.05.
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